IMMUNOVANT ($IMVT) is expected to release its quarterly earnings data on Friday, October 31st before market open, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.73 per share.
You can see Quiver Quantitative's $IMVT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
IMMUNOVANT Insider Trading Activity
IMMUNOVANT insiders have traded $IMVT stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $IMVT stock by insiders over the last 6 months:
- JAY S STOUT (Chief Technology Officer) has made 0 purchases and 4 sales selling 8,429 shares for an estimated $150,889.
- MICHAEL GEFFNER (Chief Medical Officer) has made 0 purchases and 4 sales selling 7,412 shares for an estimated $133,402.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
IMMUNOVANT Hedge Fund Activity
We have seen 100 institutional investors add shares of IMMUNOVANT stock to their portfolio, and 91 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. added 2,534,323 shares (+316.0%) to their portfolio in Q2 2025, for an estimated $40,549,168
- FMR LLC added 1,358,160 shares (+7.9%) to their portfolio in Q2 2025, for an estimated $21,730,560
- HOOD RIVER CAPITAL MANAGEMENT LLC removed 1,175,763 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $18,812,208
- VIKING GLOBAL INVESTORS LP removed 1,114,827 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $17,837,232
- MORGAN STANLEY added 999,011 shares (+76.3%) to their portfolio in Q2 2025, for an estimated $15,984,176
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 984,132 shares (+16.7%) to their portfolio in Q2 2025, for an estimated $15,746,112
- PRINCIPAL FINANCIAL GROUP INC removed 760,608 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,169,728
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
IMMUNOVANT Analyst Ratings
Wall Street analysts have issued reports on $IMVT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 09/30/2025
- B of A Securities issued a "Buy" rating on 08/12/2025
To track analyst ratings and price targets for IMMUNOVANT, check out Quiver Quantitative's $IMVT forecast page.
IMMUNOVANT Price Targets
Multiple analysts have issued price targets for $IMVT recently. We have seen 5 analysts offer price targets for $IMVT in the last 6 months, with a median target of $30.0.
Here are some recent targets:
- Danielle Brill from Truist Securities set a target price of $16.0 on 10/14/2025
- Brian Cheng from JP Morgan set a target price of $33.0 on 09/30/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $35.0 on 09/04/2025
- Jason Gerberry from B of A Securities set a target price of $30.0 on 08/12/2025
- Ashwani Verma from UBS set a target price of $18.0 on 07/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
